Interview with Erika Koppers, COO & GM, Roche SA
You have worked at Roche for several years as Business unit Manager. Therefore you are familiar with the strategy of the company and the intricacies of the job. The new…
Address: 15e Riley Road
Bedfordview 2008 ,South Africa
Tel: +27 11 087 0000
iNova Pharmaceuticals develops and markets a range of over-the-counter and prescription medicines to Australasia, Asia-Pacific, South Africa, the Americas and other international markets.
iNova has a broad range of prescription medicines and consumer healthcare products in several therapy areas including pain management, weight management, allergy, sexual health, dermatology, cardiology and respiratory health.
Among the wide variety of products iNova offers in our commitment to improving people’s health and well being are Australian made and owned market leading brands Difflam™, Duro-Tuss™, Hiprex™, Metsal™ and Cal-Sup™. We are also proud to make available to patients and consumers Azep®, Eyezep®, ZepAllergy™ and Rinar™.
Our broad product range, available in pharmacies only, comes from a heritage of many years of innovation and, more recently, in-licensed products. Strict quality assurance and control procedures help to ensure iNova produces and markets brands meeting the most rigorous quality standards. Our products are prescribed by specialist health care providers and general practitioners across the Region and supported by pharmacy recommendation.
The availability of our marketed products and information we lawfully can provide varies among countries. This website contains information on products which is targeted to a wide range of audiences and may contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
You have worked at Roche for several years as Business unit Manager. Therefore you are familiar with the strategy of the company and the intricacies of the job. The new…
Having spent two months as the head of Novartis South Africa, what is your first assignment as General Manager, could you share with our readers what were the surprises for…
Mr. Miller, you have been Vice President and Managing Director of Mylan’s operations in South Africa since 2008. What mission were you assigned back then, and in those three years,…
South Africa carries one of the world’s most disproportionate disease burdens, the worst of so-called westernised diseases, such as cardiac disease, diabetes etc on the one hand and the developmental…
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
Focus Reports is back in South Africa as part of a second set of reports on the BRICS. What would you say are the main changes in the market since…
South Africa is at the moment one of the world’s most exciting and dynamic markets at the moment as Mr. Omar Ehsan was telling us, the most exciting market he…
Could you introduce to our readers MC Pharma’s business model in the South African market as well as the main milestones in the company’s development over the recent years? MC…
Mr. Daniel, after working with Pfizer Australia, working in Hong Kong as Regional Marketing Director for the Asian operation and in Japan, you have been the first South African appointed…
South Africa has recently achieved the 1st Millennium Development Goal (MDG) – reducing the proportion of the population living on less than 1 USD a day by half – but…
Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of employees for multinational organizations.…
See our Cookie Privacy Policy Here
